psychedelics investing A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
psychedelics investing Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
psychedelics investing Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
psychedelics investing Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
psychedelics investing Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
psychedelics investing Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
psychedelics investing Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
psychedelics investing Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
psychedelics investing Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
psychedelics investing  Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
psychedelics investing Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
psychedelics investing Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635
Blue Jay Gold Announces Arrival of LithologIQ Hyperspectral Core Scanning System at the Steller Project
Metalsource Mining Continues to Define High Grade Polymetallic Core at Silver Hill with 33 Metre down Plunge Step Out
Star Copper Expands Copper-Gold Portfolio with Two Advanced District-Scale Exploration Assets in British Columbia
